<DOC>
	<DOCNO>NCT01259726</DOCNO>
	<brief_summary>The objective study : ( 1 ) evaluate safety tolerability VP 20621 dose orally 14 day adults previously treat CDI ; ( 2 ) characterize frequency duration stool colonization VP 20621 strain C. difficile ; ( 3 ) evaluate efficacy VP 20621 prevention recurrence CDI ; ( 4 ) select dose regimen VP 20621 used future study .</brief_summary>
	<brief_title>Safety Efficacy Study VP20621 Prevention Recurrent Clostridium Difficile Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<criteria>1 . Adult subject , 18 year age , understand risk benefit participation provide write informed consent study . 2 . Subjects experience first event first recurrence clostridium difficile ( CDI ) within last 28 day successfully treat antibiotic CDI . 3 . Subjects medically stable . 4 . Subjects willing able comply study procedure visit schedule outline . 5 . If female postmenopausal , surgically sterile agree follow acceptable method birth control . 1 . Subjects 2 episode CDI within last 6 month . 2 . Subjects diagnose Inflammatory Bowel Disease , active Irritable Bowel Syndrome , celiac disease , active gastroparesis , toxic megacolon . 3 . GI surgery within 6 week day randomization 4 . Have know immunodeficiency disorder , HIV Infection 5 . Pregnant breast feeding female . 6 . Concurrent acute lifethreatening disease . 7 . Inability tolerate oral liquid . 8 . Have absolute neutrophil count &lt; 1000/mm3 screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Diarrhea</keyword>
	<keyword>Clostridium difficile</keyword>
	<keyword>Clostridium infection</keyword>
	<keyword>Signs Symptoms Digestive</keyword>
	<keyword>Bacterial Infections</keyword>
	<keyword>Pharmacologic Actions</keyword>
</DOC>